Hepcinat Lp
Chronic Hepatitis C
90mg + 400mg
Ledipasvir and sofosbuvir tablets for chronic hepatitis C. One of the newer direct-acting antiviral combinations, taken as a course to clear the virus.
From$47.21/ tabletView
Ledipasvir
One ledipasvir product appears in this catalogue: Hepcinat LP, the generic version of Harvoni, a 90 mg plus 400 mg tablet that pairs ledipasvir with sofosbuvir to treat chronic hepatitis C.
Key points
- Ledipasvir is an NS5A inhibitor: it blocks the NS5A protein, which hepatitis C needs to assemble new viral particles; without it, the virus cannot spread within the body.
- Sofosbuvir, the other ingredient in this tablet, is a nucleotide polymerase inhibitor that stops the virus from copying its genetic material.
- Ledipasvir and sofosbuvir labelling carries a warning about hepatitis B reactivation during or after treatment.
How does ledipasvir work?
Ledipasvir blocks the NS5A protein, which hepatitis C needs to assemble new viral particles. Without it, the virus cannot spread within the body. Sofosbuvir, the other ingredient in this tablet, stops the enzyme that copies the virus’s genetic material. The two attacks target different steps in the viral life cycle, which is why ledipasvir is not sold as a single-ingredient product.
Hepcinat LP, a Natco Pharma product, carries the same two ingredients and strengths as Harvoni, the brand-name version. For more on the condition this treats, see Chronic Hepatitis C, or browse the wider Hepatitis Treatment range.